Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rapcabtagene autoleucel - Novartis

Next Previous
Drug Profile

Rapcabtagene autoleucel - Novartis

Alternative Names: Anti-CD19 CAR-T cell therapy - Novartis; Anti-CD19 chimeric antigen receptor T cell therapy - Novartis; YTB-323; YTB323 Anti CD19 chimeric antigen receptor T cell therapy - Novartis

Latest Information Update: 30 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diffuse large B cell lymphoma
  • Phase II Granulomatosis with polyangiitis; Microscopic polyangiitis; Myositis; Systemic scleroderma
  • Phase I/II Lupus nephritis; Multiple sclerosis; Myasthenia gravis; Rheumatoid arthritis; Sjogren's syndrome; Systemic lupus erythematosus
  • Phase I Chronic lymphocytic leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 30 Sep 2025 Adverse event, efficacy and pharmacodynamic data from a phase I/II trial in Systemic lupus erythematosus presented at the 26th Annual Congress of the European League Against Rheumatism (EULAR-2025)
  • 20 Jun 2025 Phase-I/II clinical trials in Rheumatoid arthritis (Treatment-resistant) in Singapore (Parenteral) (NCT07048197)
  • 20 Jun 2025 Phase-I/II clinical trials in Sjogren's syndrome (Treatment-resistant) in Singapore (Parenteral) (NCT07048197)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top